Targets › CD73
2 programs from 2 companies in 2 trials: 2 Phase 1; Oncology; next expected readout Feb 2027.
Open in Phaseline: the race on CD73, likelihood bands and readouts
| Company | Drug | Targets | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|---|
| GI Innovation | GI-108 Anti-CD73-IgG4 Fc-IL-2v bispecific fusion protein | CD73, IL2RA | Phase 1 | Advanced Solid Tumor | Feb 2027 |
| AP Biosciences | AP601 Bispecific antibody targeting CD73 | CD73 | Phase 1 | Solid Tumours | Dec 2027 |
Solid Tumours (1) Advanced Solid Tumor (1)
small molecule (2)
Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.